WO2006032675A1 - Aqueous pharmaceutical preparation comprising roflumilast - Google Patents
Aqueous pharmaceutical preparation comprising roflumilast Download PDFInfo
- Publication number
- WO2006032675A1 WO2006032675A1 PCT/EP2005/054723 EP2005054723W WO2006032675A1 WO 2006032675 A1 WO2006032675 A1 WO 2006032675A1 EP 2005054723 W EP2005054723 W EP 2005054723W WO 2006032675 A1 WO2006032675 A1 WO 2006032675A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical preparation
- preparation according
- roflumilast
- solution
- polyethylene glycol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
Definitions
- the present invention relates to the field of pharmaceutical technology and describes an aqueous pharmaceutical preparation comprising a slightly soluble PDE 4 inhibitor as active ingredient.
- the invention further relates also to processes for producing the pharmaceutical preparation and to the use of the pharmaceutical preparation for the treatment of disorders.
- PDE 4 inhibitors is currently undergoing advanced clinical trials, including a dosage form for oral administration comprising the active ingredient N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-difluoromethoxybenzamide (INN: roflumilast).
- PDE cyclic nucleotide phosphodiesterase
- active ingredients are proposed in WO95/01338 also for the treatment of certain disorders of the skin (such as, for example, dermatoses).
- WO00/53182 proposes the use of roflumilast or its N-oxide for the treatment of multiple sclerosis.
- WO03/099334 describes pharmaceutical preparations for slightly soluble PDE 4 inhibitors such as, for example, ointments and aqueous or oily suspensions and emulsions.
- oral dosage forms it may also be necessary and advantageous to provide an active ingredient as parenteral form (preparation intended for injection), especially for groups of patients who have problems with taking oral dosage forms.
- Parenteral preparations must be produced with particular care in order to guarantee freedom from irritation and to avoid microbial and particulate contaminants.
- the most important solvent or dispersant is water. According to the pharmacopeoia, water for injections must always be used in these cases. Active ingredients to be administered intravenously must be completely dissolved. It must furthermore be ensured during development of the preparation that no precipitation takes place during the injection. Further requirements to be mentioned for parenteral preparations are in particular good tolerability for the patient. This may depend on the aqueous preparation being rendered isotonic or approximately isotonic and having an approximately physiological pH, and on the absence of particulate contaminants. The production of parenteral preparations or of general solutions of active ingredients which are slightly soluble in water therefore involves particular problems.
- roflumilast can be dissolved in water in an amount which is sufficient for injections when alkoxylated fats are used as cosolvent. It is possible on this basis to obtain clear solutions having the properties necessary for parenteral preparations (in particular good tolerability for the patient, no particulate contaminants). In particular, the solution is also stable during storage and no precipitates of the active ingredient are observed. Furthermore, compatibility with the container material is good.
- the invention therefore relates to an aqueous pharmaceutical preparation comprising an active ingredient in a therapeutically effective and pharmacologically acceptable amount and alkoxylated fat, where the active ingredient is selected from the group consisting of roflumilast, salts of roflumilast, the N-oxide of the pyridine residue of roflumilast or salts thereof.
- the aqueous preparation is in particular a solution in which the active ingredient is completely dissolved.
- Roflumilast is the INN for a compound of the formula I
- R1 is difluoromethoxy
- R2 is cyclopropylmethoxy
- R3 is 3,5-dichloropyrid-4-yl.
- This compound has the chemical name N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4- difluoromethoxybenzamide (INN: roflumilast).
- the N-oxide of roflumilast has the chemical name 3- cyclopropylmethoxy ⁇ -difluoromethoxy-N- ⁇ .S-dichloropyrid ⁇ -yl 1-oxide)benzamide.
- Salts suitable for compounds of the formula I - depending on the substitution - are all acid addition salts but, in particular, all salts with bases. Particular mention may be made of the pharmacologically acceptable salts of the inorganic and organic acids and bases normally used in pharmaceutical technology. Pharmacologically unacceptable salts which, for example, may be the initial products of the process for preparing the compounds of the invention on the industrial scale are converted into pharmacologically acceptable salts by processes known to the skilled worker.
- water-soluble and water-insoluble acid addition salts with acids such as, for example, hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, sulphuric acid, acetic acid, citric acid, D-gluconic acid, benzoic acid, 2-(4-hydroxybenzoyl)benzoic acid, butyric acid, sulphosalicylic acid, maleic acid, lauric acid, malic acid, fumaric acid, succinic acid, oxalic acid, tartaric acid, embonic acid, stearic acid, toluenesulphonic acid, methanesulphonic acid, or 3-hydroxy-2-naphthoic acid, the acids being employed to prepare the salts in the equimolar ratio of amounts, or one differing therefrom - depending on whether the acid is monobasic or polybasic and depending on which salt is desired.
- acids such as, for example, hydrochloric acid, hydrobromic acid, phosphoric acid, ni
- salts with bases are also particularly suitable.
- basic salts which may be mentioned are lithium, sodium, potassium, calcium, magnesium, ammonium, meglumine or guanidinium salts, once again the bases being employed to prepare the salts in the equimolar ratio of amounts or one differing therefrom.
- the alkoxylated fat is preferably a polyoxyethylated fatty acid, in particular polyoxyethylated 12-hydroxystearic acid.
- This is also referred to as macrogol 15-hydroxystearate or polyethylene glycol 15-hydroxystearate.
- Products based on this are obtainable, for example, from BASF under the designation Solutol® HS 15.
- Solutol® HS 15 consists of polyglycol mono- and diesters of 12-hydroxystearic acid and approximately 30% free polyethylene glycol, where parts of the 12- hydroxy group may also be etherified with polyethylene glycol (see Technical Information Solutol® HS 15 November 2002; BASF).
- the alkoxylated fat is preferably present in a pharmaceutically acceptable amount in the dosage form according to the invention.
- the preparation according to the invention is preferably a preparation based on water, particularly preferably water for injections.
- the preparation according to the invention may if desired comprise further pharmaceutical excipients suitable for parenteral preparations. Examples which should be mentioned here are substances for improving the solubility (e.g. cosolvents and solubilizers), substances for rendering isotonic, buffers, antioxidants, chelating agents, preservatives, emulsifiers, bases or acids for setting a physiological pH or excipients for prolonging the effect.
- Suitable cosolvents are in particular ethanol, glycerol, propylene glycol and polyethylene glycol or 1 ,3- butanediol. Preference is given in this connection to propylene glycol and polyethylene glycol (especially macrogol 300/400). Solubilizers which should be mentioned are lecithin and poloxamer 188 (Pluronic F68®), with preference for poloxamer 188.
- Substances which are used for rendering isotonic and should be mentioned in particular are sodium chloride, glucose, mannitol, glycerol or else propylene glycol and polyethylene glycol.
- Preservatives mentioned in particular are p-hydroxybenzoic esters, benzyl alcohol, phenylmercury salts or chlorocresol.
- the preparation according to the invention comprises poloxamer 188 and/or polyethylene glycol as further pharmaceutical excipients.
- 100 ml of solution comprise from 0.001 to 0.1 parts by weight (gram), preferably from 0.005 to 0.09 gram of roflumilast, particularly preferably from 0.01 to 0.08 gram.
- Polyethylene glycol 15- hydroxystearate is employed in amounts of from 0.5 to 15 grams, preferably 1 to 12 grams, very particularly preferably 2 to 8 grams per 100 ml of solution.
- Poloxamer 188 is employed in amounts of from 0.01 to 5 grams, preferably 0.1 to 4 grams, very particularly preferably 0.2 to 4 grams per 100 ml of solution.
- the amount of polyethylene glycol 300 or 400 or propylene glycol is preferably from 3 to 15 grams per 100 ml of solution.
- the quantitative data are preferably data relating to solutions for injection.
- the pharmaceutical preparation according to the invention can be produced by processes familiar to the skilled person.
- the active ingredient is preferably dissolved in the alkoxylated fat, optionally with heating.
- the alkoxylated fat may if desired additionally contain poloxamer 188.
- polyethylene glycol (macrogol 300/400) and/or propylene glycol By adding polyethylene glycol (macrogol 300/400) and/or propylene glycol, an improvement in the dissolution of the active ingredient can be achieved.
- polyethylene glycol (macrogol 300/400) and/or propylene glycol can also be employed to render the preparation isotonic. After adding water to the solution of the active ingredient in the alkoxylated fat a clear solution is obtained.
- the solution obtained in this way can then be sterilized by filtration and subsequently dispensed into suitable containers such as vials or ampoules.
- suitable containers such as vials or ampoules.
- the solution can alternatively first be introduced into suitable containers, and this solution can then be subjected in the final container to a sterilization, for example by autoclaving. If the preparations according to the invention are dispensed in multidose containers a preservative is preferably added.
- a clear solution is prepared (based on Example 1) from 4 grams of polyethylene glycol 400 and 2 grams of poloxamer 188. 0.04 g of roflumilast is added, and the mixture is stirred until a clear solution is obtained. While stirring, water is slowly added to make up to 100 ml. A bulky precipitate is formed.
- Example 5
- a clear solution is prepared from 4 grams of polyethylene glycol 400 and 4 grams of poloxamer 188. 0.02 gram or 0.04 gram of roflumilast is added, and the mixture is stirred until a clear solution is obtained. While stirring, water is slowly added to make up to 100 ml. A bulky precipitate is formed in both cases.
- a clear solution is prepared from 4 grams of polyethylene glycol 400 and 20 grams of poloxamer 188. 0.02 gram or 0.04 gram of roflumilast is added, and the mixture is stirred until a clear solution is obtained. While stirring, water is slowly added to make up to 100 ml. A bulky precipitate is formed in both cases.
- the preparations of the invention can be employed for the treatment and prevention of all diseases regarded as treatable or preventable through the use of PDE 4 inhibitors.
- Selective cyclic nucleotide phosphodiesterase (PDE) inhibitors are suitable on the one hand as bronchial therapeutic agents (for the treatment of airway obstructions owing to their dilating effect but also owing to their effect increasing the respiratory rate and respiratory drive) and for eliminating erectile dysfunction owing to the vasodilating effect, but on the other hand especially for the treatment of disorders, especially of an inflammatory nature, e.g.
- mediators such as histamine, PAF (platelet-activating factor), arachidonic acid derivatives such as leukotrienes and prostaglandins, cytokines, interleukins, chemokines, alpha-, beta- and gamma- interferon, tumour necrosis factor (TNF) or oxygen free radicals and proteases.
- mediators such as histamine, PAF (platelet-activating factor), arachidonic acid derivatives such as leukotrienes and prostaglandins, cytokines, interleukins, chemokines, alpha-, beta- and gamma- interferon, tumour necrosis factor (TNF) or oxygen free radicals and proteases.
- the pharmaceutical preparations of the invention can therefore be used in human and veterinary medicine for example for the treatment and prophylaxis of the following diseases: acute and chronic (especially inflammatory and allergen-induced) airway disorders of various aetiologies (bronchitis, allergic bronchitis, bronchial asthma, COPD); dermatoses (especially of a proliferative, inflammatory and allergic nature) such as, for example, psoriasis (vulgaris), toxic and allergic contact eczema, atopic eczema, seborrhoeic eczema, lichen simplex, sunburn, pruritus in the genitoanal region, alopecia areata, hypertrophic scars, discoid lupus erythematosus, follicular and extensive pyodermas, endogenous and exogenous acne, acne rosacea and other proliferative, inflammatory and allergic skin disorders; disorders based on excessive release of TNF
- disorders of the arthritic type rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis and other arthritic states
- disorders of the immune system AIDS, multiple sclerosis
- types of shock septic shock, endotoxin shock, Gram-negative sepsis, toxic shock syndrome and ARDS (adult respiratory distress syndrome)] and generalized inflammations in the gastrointestinal region (Crohn's disease and ulcerative colitis
- the pharmaceutical preparations of the invention are also suitable for the treatment of disorders of the skin such as dermatoses (especially of a proliferative, inflammatory and allergic nature) such as, for example, psoriasis (vulgaris), toxic and allergic contact eczema, atopic eczema, seborrhoeic eczema, lichen simplex, sunburn, pruritus in the genitoanal region, alopecia areata, hypertrophic scars, discoid lupus erythematosus, follicular and extensive pyodermas, endogenous and exogenous acne, acne rosacea and other proliferative, inflammatory and allergic skin disorders.
- dermatoses especially of a proliferative, inflammatory and allergic nature
- psoriasis vulgaris
- toxic and allergic contact eczema atopic eczema
- seborrhoeic eczema
- preparations according to the invention in the form of a solution can be administered parenterally (e.g. as injection or infusion) or can also be administered topically, for example in the form of eye drops or as a nasal administration (for use on the nasal mucosa) for the treatment of the abovementioned diseases.
- the invention further relates to a method for the treatment of mammals, including humans, suffering from one of the abovementioned diseases.
- the method is characterized in that a therapeutically effective and pharmacologically suitable amount of an active pharmaceutical ingredient selected from the group of compounds roflumilast, salts of roflumilast, the N-oxide of roflumilast and salts thereof is administered to the mammal with the disease, with the active pharmaceutical ingredient being administered in a pharmaceutical preparation of the invention.
- the method is characterized in that the administration takes place by parenteral administration (injection or infusion).
- the invention further relates to a method for the treatment of mammals, including humans, suffering from one of the abovementioned diseases.
- the method is characterized in that a therapeutically effective and pharmacologically suitable amount of an active pharmaceutical ingredient selected from the group of compounds roflumilast, salts of roflumilast, the N-oxide of roflumilast and salts thereof is administered to the mammal with the disease, with the active pharmaceutical ingredient being administered in a pharmaceutical preparation of the invention.
- the method is characterized in that the administration takes place by nasal administration.
- the invention relates to the treatment of mammals, including humans, suffering from an eye disorder which is regarded as treatable or preventable through use of PDE 4 inhibitors.
- the eye disorder is preferably selected from the group of allergic conjunctivitis, conjunctivitis caused by bacteria, viruses or fungi, inflammatory states after intraocular lens implantation, inflammation of the optic nerve (neuritis nervi optici), keratitis, dry eye syndrome (keratitis sicca), uveitis, glaucoma, retinal oedema, retinitis pigmentosa and diabetic retinopathy.
- the eye disorder is preferably allergic conjunctivitis, conjunctivitis caused by bacteria, viruses or fungi, inflammatory states after intraocular lens implantation or uveitis.
- the method is characterized in that the administration takes place by administration of the preparation according to the invention to the eye, especially in the form of eye drops.
- the pharmaceutical preparations of the invention are moreover particularly suitable for administration to groups of patients who are suffering from the abovementioned diseases and have problems in taking pharmaceutical preparations to be administered orally, such as, for example, bedridden patients, patients in intensive medical care, patients with swallowing difficulties and children.
- the invention further relates to a method for the treatment of mammals, including humans, suffering from one of the abovementioned diseases.
- the method is characterized in that a therapeutically effective and pharmacologically suitable amount of an active pharmaceutical ingredient selected from the group of compounds roflumilast, salts of roflumilast, the N-oxide of roflumilast and salts thereof is administered to the mammal with the disease, with the active pharmaceutical ingredient being administered in a topical pharmaceutical preparation of the invention.
- the disease is preferably acute and chronic (especially inflammatory and allergen-induced) airway disorders of various aetiologies (bronchitis, allergic bronchitis, bronchial asthma, COPD), and disorders of the arthritic type (rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis and other arthritic states).
- the dosage forms of the invention comprise the active pharmaceutical ingredient in the dose customary for the treatment of the particular disease.
- the dosage of the active ingredient is of the order of magnitude customary for PDE inhibitors, it being possible to administer the daily dose in one or more dosage units.
- Customary dosages are disclosed for example in WO 95/01338.
- the normal dose on systemic therapy (oral) is between 0.001 and 3 mg per kilogram and day.
- Dosage forms preferred according to the invention for parenteral administration contain from 0.005 mg to 5 mg of roflumilast, preferably from 0.01 mg to 2.5 mg, particularly preferably 0.1 mg to 0.5 mg of roflumilast per dosage unit.
- Examples of pharmaceutical preparations of the invention contain 0.01 mg, 0.1 mg, 0.125 mg, 0.25 mg and 0.5 mg of roflumilast per dosage unit.
Abstract
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2005286476A AU2005286476B2 (en) | 2004-09-22 | 2005-09-21 | Aqueous pharmaceutical preparation comprising roflumilast |
EP05794694A EP1796668B1 (en) | 2004-09-22 | 2005-09-21 | Aqueous pharmaceutical preparation comprising roflumilast |
PL05794694T PL1796668T3 (en) | 2004-09-22 | 2005-09-21 | Aqueous pharmaceutical preparation comprising roflumilast |
DE602005009848T DE602005009848D1 (en) | 2004-09-22 | 2005-09-21 | AQUEOUS PHARMACEUTICAL PREPARATION WITH ROFLUMILAST |
JP2007531767A JP5044404B2 (en) | 2004-09-22 | 2005-09-21 | Aqueous pharmaceutical preparations containing roflumilast |
RSP-2008/0591A RS50641B (en) | 2004-09-22 | 2005-09-21 | Aqueous pharmaceutical preparation comprising roflumilast |
MEP-2008-797A ME01050B (en) | 2004-09-22 | 2005-09-21 | Aqueous pharmaceutical preparation comprising roflumilast |
DK05794694T DK1796668T3 (en) | 2004-09-22 | 2005-09-21 | Aqueous pharmaceutical composition comprising roflumilast |
CA2580397A CA2580397C (en) | 2004-09-22 | 2005-09-21 | Aqueous pharmaceutical preparation comprising roflumilast and an alkoxylated fat |
US11/662,887 US9205044B2 (en) | 2004-09-22 | 2005-09-21 | Aqueous pharmaceutical preparation comprising roflumilast |
HR20080640T HRP20080640T3 (en) | 2004-09-22 | 2008-12-09 | Aqueous pharmaceutical preparation comprising roflumilast |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102004046235A DE102004046235A1 (en) | 2004-09-22 | 2004-09-22 | drug preparation |
DE102004046235.6 | 2004-09-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006032675A1 true WO2006032675A1 (en) | 2006-03-30 |
Family
ID=35447576
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2005/054723 WO2006032675A1 (en) | 2004-09-22 | 2005-09-21 | Aqueous pharmaceutical preparation comprising roflumilast |
Country Status (17)
Country | Link |
---|---|
US (1) | US9205044B2 (en) |
EP (1) | EP1796668B1 (en) |
JP (1) | JP5044404B2 (en) |
AT (1) | ATE408405T1 (en) |
AU (1) | AU2005286476B2 (en) |
CA (1) | CA2580397C (en) |
CY (1) | CY1109407T1 (en) |
DE (2) | DE102004046235A1 (en) |
DK (1) | DK1796668T3 (en) |
ES (1) | ES2314718T3 (en) |
HR (1) | HRP20080640T3 (en) |
ME (1) | ME01050B (en) |
PL (1) | PL1796668T3 (en) |
PT (1) | PT1796668E (en) |
RS (1) | RS50641B (en) |
SI (1) | SI1796668T1 (en) |
WO (1) | WO2006032675A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102793684A (en) * | 2011-05-26 | 2012-11-28 | 杭州赛利药物研究所有限公司 | Roflumilast liquid preparation and preparation method thereof |
WO2014012954A1 (en) | 2012-07-18 | 2014-01-23 | Takeda Gmbh | Treatment of partly controlled or uncontrolled severe asthma |
CN105287366A (en) * | 2014-06-18 | 2016-02-03 | 张蕊 | Vitamin K1 injection and preparation method thereof |
US10357486B2 (en) | 2013-08-16 | 2019-07-23 | Universiteit Maastricht | Treatment of cognitive impairment with PDE4 inhibitor |
US11400058B2 (en) | 2010-03-12 | 2022-08-02 | Berg Llc | Intravenous formulations of coenzyme Q10 (CoQ10) and methods of use thereof |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY140561A (en) | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
US8795634B2 (en) * | 2008-09-12 | 2014-08-05 | Critical Pharmaceuticals Limited | Absorption of therapeutic agents across mucosal membranes or the skin |
AU2010247750B2 (en) | 2009-05-11 | 2016-09-22 | Berg Llc | Methods for treatment of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers |
GB0915480D0 (en) * | 2009-09-04 | 2009-10-07 | Arecor Ltd | Stable formulation of factor viii |
WO2012121988A2 (en) * | 2011-03-07 | 2012-09-13 | Celgene Corporation | Methods for treating diseases using isoindoline compounds |
JP6092844B2 (en) | 2011-04-04 | 2017-03-08 | バーグ エルエルシー | Treatment of central nervous system tumors |
PE20180414A1 (en) | 2011-06-17 | 2018-03-01 | Berg Llc | INHALABLE PHARMACEUTICAL COMPOSITIONS |
SG11201508272YA (en) | 2013-04-08 | 2015-11-27 | Berg Llc | Treatment of cancer using coenzyme q10 combination therapies |
EA034143B1 (en) | 2013-09-04 | 2020-01-09 | Берг Ллк | Methods of treatment of cancer by continuous infusion of coenzyme q10 |
KR101878621B1 (en) | 2014-10-24 | 2018-07-13 | 히사미쓰 세이야꾸 가부시키가이샤 | Prodrug |
EP3319608A4 (en) * | 2015-07-07 | 2019-04-03 | LifeRaft Biosciences, Inc. | Reduced sodium poloxamer-188 formulations and methods for use |
US11129818B2 (en) | 2017-06-07 | 2021-09-28 | Arcutis Biotherapeutics, Inc. | Topical roflumilast formulation having improved delivery and plasma half life |
US9895359B1 (en) | 2017-06-07 | 2018-02-20 | Arcutis, Inc. | Inhibition of crystal growth of roflumilast |
US11534493B2 (en) * | 2017-09-22 | 2022-12-27 | Arcutis Biotherapeutics, Inc. | Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents |
KR102117525B1 (en) * | 2018-07-09 | 2020-06-01 | 건양대학교 산학협력단 | Pharmaceutical Composition for Preventing or Treating Chronic Rhinosinusitis Comprising PDE4B Inhibitor |
BR112022015104A2 (en) | 2020-01-31 | 2022-09-27 | Arcutis Biotherapeutics Inc | METHOD TO IMPROVE THE DISTRIBUTION AND EXTEND THE PLASMATIC HALF-LIFE OF A ROFLUMILAST COMPOSITION AND USE OF A COMPOSITION |
WO2021157569A1 (en) * | 2020-02-03 | 2021-08-12 | 千寿製薬株式会社 | Use of polyether compound |
WO2022169615A1 (en) | 2021-02-05 | 2022-08-11 | Arcutis Biotherapeutics, Inc. | Roflumilast formulations with an improved pharmacokinetic profile |
CN116867480A (en) * | 2021-02-10 | 2023-10-10 | 洛利克斯治疗有限公司 | Methods of ocular delivery of roflumilast |
US20240108609A1 (en) | 2022-09-15 | 2024-04-04 | Arcutis Biotherapeutics, Inc. | Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2165192C (en) | 1993-07-02 | 2001-04-24 | Hermann Amschler | Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors |
DE69937343T2 (en) * | 1998-05-07 | 2008-07-24 | Corixa Corp., Seattle | ADJUVANEAN COMPOSITION AND METHODS OF USE THEREOF |
AU3284000A (en) | 1999-03-10 | 2000-09-28 | Byk Gulden Lomberg Chemische Fabrik Gmbh | 3-cyclopropylmethoxy-4-difluoromethoxy-n-(3,5-dichloropyrid- 4-yl)benzamide in the treatment of multiple sclerosis |
US20020193393A1 (en) * | 2001-03-07 | 2002-12-19 | Michel Pairet | Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors |
MY140561A (en) * | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
DK2020243T3 (en) * | 2002-05-28 | 2018-11-19 | Astrazeneca Ab | Pharmaceutical composition which can be applied topically |
US20030235631A1 (en) * | 2002-06-17 | 2003-12-25 | Pfizer Inc. | Combination treatment for depression and anxiety |
US20040058950A1 (en) * | 2002-07-09 | 2004-03-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors |
DE10230769A1 (en) * | 2002-07-09 | 2004-01-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New drug compositions based on new anticholinergics and PDE-IV inhibitors |
PL213925B1 (en) * | 2002-07-19 | 2013-05-31 | Abbott Biotech Ltd | Treatment of tnf ó related disorders |
-
2004
- 2004-09-22 DE DE102004046235A patent/DE102004046235A1/en not_active Withdrawn
-
2005
- 2005-09-21 PL PL05794694T patent/PL1796668T3/en unknown
- 2005-09-21 AU AU2005286476A patent/AU2005286476B2/en not_active Ceased
- 2005-09-21 CA CA2580397A patent/CA2580397C/en not_active Expired - Fee Related
- 2005-09-21 US US11/662,887 patent/US9205044B2/en not_active Expired - Fee Related
- 2005-09-21 ME MEP-2008-797A patent/ME01050B/en unknown
- 2005-09-21 AT AT05794694T patent/ATE408405T1/en active
- 2005-09-21 ES ES05794694T patent/ES2314718T3/en active Active
- 2005-09-21 RS RSP-2008/0591A patent/RS50641B/en unknown
- 2005-09-21 DK DK05794694T patent/DK1796668T3/en active
- 2005-09-21 SI SI200530511T patent/SI1796668T1/en unknown
- 2005-09-21 JP JP2007531767A patent/JP5044404B2/en not_active Expired - Fee Related
- 2005-09-21 DE DE602005009848T patent/DE602005009848D1/en active Active
- 2005-09-21 EP EP05794694A patent/EP1796668B1/en active Active
- 2005-09-21 PT PT05794694T patent/PT1796668E/en unknown
- 2005-09-21 WO PCT/EP2005/054723 patent/WO2006032675A1/en active Application Filing
-
2008
- 2008-12-09 HR HR20080640T patent/HRP20080640T3/en unknown
- 2008-12-10 CY CY20081101429T patent/CY1109407T1/en unknown
Non-Patent Citations (3)
Title |
---|
"ROFLUMILAST APTA 2217, B9302-107, BY217, BYK 20869", DRUGS IN R & D, ADIS INTERNATIONAL, AUCKLAND, NZ, vol. 5, no. 3, May 2004 (2004-05-01), pages 176 - 181, XP008036613, ISSN: 1174-5886 * |
KUMAR RAKESH K ET AL: "Inhibition of inflammation and remodeling by roflumilast and dexamethasone in murine chronic asthma.", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 307, no. 1, October 2003 (2003-10-01), pages 349 - 355, XP002358798, ISSN: 0022-3565 * |
STRICKLEY R G: "SOLUBILIZING EXCIPIENTS IN ORAL AND INJECTABLE FORMULATIONS", PHARMACEUTICAL RESEARCH, NEW YORK, NY, US, vol. 21, no. 2, February 2004 (2004-02-01), pages 201 - 230, XP009035738, ISSN: 0724-8741 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11400058B2 (en) | 2010-03-12 | 2022-08-02 | Berg Llc | Intravenous formulations of coenzyme Q10 (CoQ10) and methods of use thereof |
CN102793684A (en) * | 2011-05-26 | 2012-11-28 | 杭州赛利药物研究所有限公司 | Roflumilast liquid preparation and preparation method thereof |
WO2014012954A1 (en) | 2012-07-18 | 2014-01-23 | Takeda Gmbh | Treatment of partly controlled or uncontrolled severe asthma |
US10357486B2 (en) | 2013-08-16 | 2019-07-23 | Universiteit Maastricht | Treatment of cognitive impairment with PDE4 inhibitor |
CN105287366A (en) * | 2014-06-18 | 2016-02-03 | 张蕊 | Vitamin K1 injection and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
US9205044B2 (en) | 2015-12-08 |
CY1109407T1 (en) | 2014-07-02 |
ME01050B (en) | 2012-10-20 |
DE102004046235A1 (en) | 2006-03-30 |
CA2580397A1 (en) | 2006-03-30 |
RS50641B (en) | 2010-06-30 |
US20070259009A1 (en) | 2007-11-08 |
HRP20080640T3 (en) | 2009-01-31 |
AU2005286476A1 (en) | 2006-03-30 |
EP1796668B1 (en) | 2008-09-17 |
ES2314718T3 (en) | 2009-03-16 |
PL1796668T3 (en) | 2009-02-27 |
ATE408405T1 (en) | 2008-10-15 |
CA2580397C (en) | 2013-07-30 |
DE602005009848D1 (en) | 2008-10-30 |
SI1796668T1 (en) | 2009-02-28 |
PT1796668E (en) | 2008-12-22 |
DK1796668T3 (en) | 2009-02-02 |
AU2005286476B2 (en) | 2011-11-10 |
JP2008513416A (en) | 2008-05-01 |
JP5044404B2 (en) | 2012-10-10 |
EP1796668A1 (en) | 2007-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2580397C (en) | Aqueous pharmaceutical preparation comprising roflumilast and an alkoxylated fat | |
US20210116207A1 (en) | Topically applicable pharmaceutical preparation | |
KR100533407B1 (en) | Nmda receptor agonist pharmaceutical compositions | |
EP2938325B1 (en) | Diclofenac composition | |
JP2015057397A (en) | Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination therapy | |
JP6818019B2 (en) | Injectable pharmaceutical composition of lefamulin | |
US20080045572A1 (en) | Pharmaceutical Composition Comprising Roflumilast or the N-Oxide of Roflumilast | |
JP5434981B2 (en) | Eye drops | |
JP4779382B2 (en) | Composition for eye drops | |
JP4961671B2 (en) | Eye drops | |
JP2000219628A (en) | Previously mixed injectable composition of alatrofloxacin | |
US20050208081A1 (en) | Use of moxaverin for treating erectile dysfunction, forms of dementia or diseases associated to an arteriosclerotic occlusion |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007531767 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2580397 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11662887 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005794694 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005286476 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2005286476 Country of ref document: AU Date of ref document: 20050921 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005794694 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11662887 Country of ref document: US |
|
WWG | Wipo information: grant in national office |
Ref document number: 2005794694 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: P-2008/0591 Country of ref document: RS |